Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

Eli Lilly (LLY) raised prices of its GLP-1 weight-loss injectable in the UK this week, with plans to do the same in other ...

"Forever" PFAS chemicals might hamper a teenager's ability to drop excess weight, even if they've undergone weight-loss ...

It seems to be holding off on price adjustments demanded by President Trump.

There’s a new kind of nosy parker in the United States, a person who seems to think it’s fine to blurt out “Are you on ...

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

Eli Lilly's pricing strategy for GLP-1 drugs is expected to have minimal margin impact, with BofA reaffirming a $900 price ...

What Happened: Alvarez's recent move, as outlined in a Form 4 filing with the U.S. Securities and Exchange Commission on Thursday, involves purchasing 758 shares of Eli Lilly. The total transaction ...

The cost of Mounjaro, a popular weight-loss injection, is set to rise sharply in the UK – from £122 to £330 – a 170 per cent ...

Eli Lilly said the increase brings the UK price in line with other European markets, though NHS availability will be unaffected.